IRVINE, Calif., June 15, 2017 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS) today announced that its shareholders haveapproved the previously announced definitive agreement under which an affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Syneron Candela for $11.00 per share in cash in a transaction
93.3% of the ordinary shares voting at the special shareholder meeting were voted in favor of the Merger Agreement.
The acquisition is expected to be completed in mid-July, subject to the satisfaction of the remaining closing conditions.
About Syneron CandelaSyneron Candela is a leading global non-surgical aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, women's intimate health, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company has a wide portfolio of trusted, leading products including UltraShape Power, VelaShape, CO2RE, CO2RE Intima, GentleLase, VBeam Perfecta, PicoWay, Profound and el?s Plus.
Founded in 2000 and headquartered in Israel, Syneron Candela has R&D and manufacturing operations in Israel and the U.S. The company markets, services and supports its products in nearly 100 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
Forward Looking StatementsThis news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include statements regarding the expected timing of the proposed acquisition. Such "forward looking statements" involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from those projected. Achievement of these results by the Company may be affected by many factors, including, but not limited to, risks and uncertainties regarding the ability to close the proposed transaction on the proposed terms and within the anticipated time period, or at all, which is dependent on the parties' ability to satisfy certain closing conditions? the risk that the benefits of the potential transaction may not be fully realized or may take longer to realize than expected? disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; the risk that the Company's business may not perform as expected; as well as general economic conditions. Additional information regarding these and other factors is contained in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F. The statements made by the Company are based upon management's current expectations and the Company undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this release except as required by law.
For additional information, please visit http://www.syneron-candela.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/syneron-candela-announces-shareholder-approval-of-proposed-acquisition-by-funds-advised-by-apax-partners-300474635.html
SOURCE Syneron Medical Ltd.
Subscribe to our Free Newsletters!
Nocturnal polyuria refers to increased urine output during night, without an associated increase in ...
Nootropics are drugs or substances which improve cognition that are being increasingly used ...
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...View All